Literature DB >> 16541250

Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors.

Nelilma Correia Romeiro1, Magaly Girão Albuquerque, Ricardo Bicca de Alencastro, Malini Ravi, Anton J Hopfinger.   

Abstract

The p38-mitogen-activated protein kinases (p38-MAPKs) belong to a family of serine-threonine kinases activated by pro-inflammatory or stressful stimuli that are known to be involved in several diseases. Their biological importance, related to the release of inflammatory pro-cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1), has generated many studies aiming at the development of selective inhibitors for the treatment of inflammatory diseases. In this work, we developed receptor-based three dimensional (3D) quantitative structure-activity relationship (QSAR) models for a series of 33 pyridinyl imidazole compounds [Liverton et al. (1999) 42:2180], using a methodology named free-energy force-field (FEFF) [Tokarski and Hopfinger (1997) 37:792], in which scaled intra- and intermolecular energy terms of the Assisted Model Building Energy Refinement (AMBER) force field combined with a hydration-shell solvation model are the independent variables used in the QSAR studies. Multiple temperature molecular-dynamics simulations (MDS) of ligand-protein complexes and genetic-function approximation (GFA) were employed using partial least squares (PLS) as the fitting functions to develop FEFF-3D-QSAR models for the binding process. The best model obtained in the FEFF-3D-QSAR receptor-dependent (RD) method shows the importance of the van der Waals energy change upon binding and the electrostatic energy in the interaction of ligands with the receptor. The QSAR equations described here show good predictability and may be regarded as representatives of the binding process of ligands to p38-MAPK. Additionally, we have compared the top FEFF-3D-QSAR model with receptor independent (RI) 4D-QSAR models developed in a recent study [Romeiro et al. (2005) 19:385].

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16541250     DOI: 10.1007/s00894-006-0106-2

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  31 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands.

Authors:  Hugo Verli; Magaly Girão Albuquerque; Ricardo Bicca de Alencastro; Eliezer J Barreiro
Journal:  Eur J Med Chem       Date:  2002-03       Impact factor: 6.514

Review 3.  Structure-based inhibitor design targeting HIV-1 integrase.

Authors:  I-Jen Chen; Nouri Neamati; Alexander D MacKerell
Journal:  Curr Drug Targets Infect Disord       Date:  2002-09

Review 4.  p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.

Authors:  J C Lee; S Kassis; S Kumar; A Badger; J L Adams
Journal:  Pharmacol Ther       Date:  1999 May-Jun       Impact factor: 12.310

5.  Potent inhibitors of the MAP kinase p38.

Authors:  J R Henry; K C Rupert; J H Dodd; I J Turchi; S A Wadsworth; D E Cavender; P H Schafer; J J Siekierka
Journal:  Bioorg Med Chem Lett       Date:  1998-12-01       Impact factor: 2.823

Review 6.  Protein kinase cascades activated by stress and inflammatory cytokines.

Authors:  J M Kyriakis; J Avruch
Journal:  Bioessays       Date:  1996-07       Impact factor: 4.345

7.  Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: application to a set of peptidometic renin inhibitors.

Authors:  J S Tokarski; A J Hopfinger
Journal:  J Chem Inf Comput Sci       Date:  1997 Jul-Aug

8.  p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.

Authors:  A M Redman; J S Johnson; R Dally; S Swartz; H Wild; H Paulsen; Y Caringal; D Gunn; J Renick; M Osterhout; J Kingery-Wood; R A Smith; W Lee; J Dumas; S M Wilhelm; T J Housley; A Bhargava; G E Ranges; A Shrikhande; D Young; M Bombara; W J Scott
Journal:  Bioorg Med Chem Lett       Date:  2001-01-08       Impact factor: 2.823

9.  Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors.

Authors:  Nelilma Correia Romeiro; Magaly Girão Albuquerque; Ricardo Bicca de Alencastro; Malini Ravi; Anton J Hopfinger
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

10.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.

Authors:  J Han; J D Lee; L Bibbs; R J Ulevitch
Journal:  Science       Date:  1994-08-05       Impact factor: 47.728

View more
  4 in total

1.  QSID Tool: a new three-dimensional QSAR environmental tool.

Authors:  Dong Sun Park; Jae Min Kim; Young Bok Lee; Chang Ho Ahn
Journal:  J Comput Aided Mol Des       Date:  2008-05-30       Impact factor: 3.686

2.  Antiprotozoal Nitazoxanide Derivatives: Synthesis, Bioassays and QSAR Study Combined with Docking for Mechanistic Insight.

Authors:  Thomas Scior; Jorge Lozano-Aponte; Subhash Ajmani; Eduardo Hernández-Montero; Fabiola Chávez-Silva; Emanuel Hernández-Núñez; Rosa Moo-Puc; Andres Fraguela-Collar; Gabriel Navarrete-Vázquez
Journal:  Curr Comput Aided Drug Des       Date:  2015       Impact factor: 1.606

3.  Residue-ligand interaction energy (ReLIE) on a receptor-dependent 3D-QSAR analysis of S- and NH-DABOs as non-nucleoside reverse transcriptase inhibitors.

Authors:  Monique Araújo de Brito; Carlos Rangel Rodrigues; José Jair Viana Cirino; Jocley Queiroz Araújo; Thiago Honório; Lúcio Mendes Cabral; Ricardo Bicca de Alencastro; Helena Carla Castro; Magaly Girão Albuquerque
Journal:  Molecules       Date:  2012-06-25       Impact factor: 4.411

4.  A new structure-based QSAR method affords both descriptive and predictive models for phosphodiesterase-4 inhibitors.

Authors:  Xialan Dong; Weifan Zheng
Journal:  Curr Chem Genomics       Date:  2008-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.